Alzheimer’s disease is a ticking time bomb for public health around the world. If we don’t act now, it will single-handedly devastate global healthcare systems.
A unique public-private partnership aims to change the face of Alzheimer’s dementia research by avoiding the duplication of research efforts. Danielle Barron speaks to those involved to find out why this new approach may finally lead to effective treatments for the condition.
As pharmaceutical companies compete to bring new drugs to market, there is an increasing emphasis on the need for patient centricity – to retain patient volunteers and produce quality data. We spoke to Duncan Cantor, Director of Communications, Boehringer Ingelheim, about the importance of patient centricity in clinical trials.